IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#2374
Positioning
Market Dominance
Manufacturing
Measuring And Control Equipment
$120M
Thomas D. Hull
Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. Its products include steel, wood, laminate furniture, fume hoods, biological safety cabinets, laminar flow and ductless hoods. The company sells its products primarily through dealers, commissioned agents, and a national distributor.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = KEQU ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$KEQU KEWAUNEE SCIENTIFIC CORP /DE/ | 48 | 65 | 68 | 25 | 12.1x | 10.1x | 14.1% | 5.3% | 28.5% | 6.3% | 4.1% | 44.9% | 0.0% | 49.0x | $120M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
KEWAUNEE SCIENTIFIC CORP /DE/ (KEQU) receives a "Reduce" rating with a composite score of 47.7/100. It ranks #2374 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Thomas D. Hull
Chief Executive Officer
Labor Force
890
65
21
58
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for KEQU
Lagging peers — losers tend to keep underperforming
Trading at a discount to fundamentals — favorable entry valuation
High profitability & efficiency — strong quality floor supports entry
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for KEQU.
View All RatingsMaterial decline in asset turnover efficiency detected
High margin volatility — erratic forensic earnings quality
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 65 | 67 | -2NEUTRAL |
| MOMENTUM | 25 | 5 | +20ALPHA |
| VALUATION | 68 | 60 | +8ALPHA |
| INVESTMENT | 21 | 3 | +18ALPHA |
| STABILITY | 58 | 47 | +11ALPHA |
| SHORT INT | 23 | 8 | +15ALPHA |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy 14.1% (sector -2.5%)
GM 29% vs sector 43%, OM 6% vs sector 1%
Capital turnover N/A
Rev growth 45%, 11yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
KEWAUNEE SCIENTIFIC CORP /DE/ receives a Reduce rating from our analysis, with a composite score of 47.7/100 and 2 out of 5 stars, ranking #2374 out of 7,333 stocks. KEQU's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
KEQU earns a quality score of 65/100, indicating above-average business quality. The company reports a return on equity of 14.1% (sector avg: -2.5%), gross margins of 28.5% (sector avg: 42.5%), net margins of 4.1% (sector avg: -0.2%). Companies in this tier generally demonstrate consistent profitability and efficient capital deployment, though they may face some competitive pressure.
KEQU's value score of 68/100 indicates the stock is fairly valued based on its current fundamentals. Key valuation metrics include a P/E ratio of 12.08x, an EV/EBITDA of 10.08x, a P/B ratio of 1.70x. At this level, neither a clear bargain nor overpriced, the stock's attractiveness depends more on forward growth expectations and qualitative factors.
KEWAUNEE SCIENTIFIC CORP /DE/'s investment score of 21/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 44.9% vs. a sector average of 5.9% and a return on assets of 5.3% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
KEWAUNEE SCIENTIFIC CORP /DE/ is experiencing notably weak momentum with a score of just 25/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth stands at 44.9% year-over-year, while a beta of 1.07 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
With a stability score of 58/100, KEQU exhibits average financial resilience. Key stability metrics include a beta of 1.07 and a debt-to-equity ratio of 49.00x (sector avg: 0.2x). While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.
KEWAUNEE SCIENTIFIC CORP /DE/'s short interest score of 23/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include elevated leverage (D/E: 49.00x), micro-cap liquidity risk. At $120M (micro-cap), KEQU carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
KEWAUNEE SCIENTIFIC CORP /DE/ is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #2374 of 7,333 overall (68th percentile). Key comparisons include ROE of 14.1% exceeding the -2.5% sector median and operating margins of 6.3% above the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While KEQU currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Investment (21) would have the largest impact on the composite score.
EV/EBITDA 12% BELOW SECTOR MEDIAN (FAVORABLE)
ROE 668% BELOW SECTOR MEDIAN
Gross Margin 33% BELOW SECTOR MEDIAN
AUDIT DATA AS OF OCT 31, 2025 (Q3 FY2025)
We rate KEWAUNEE SCIENTIFIC CORP /DE/ (KEQU) as a Reduce with a composite score of 47.7/100 at a current price of $43.14. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential and elevated risk of underperformance relative to peers over the next 12 months.
The rating is primarily driven by strength in value (68th percentile) and quality (65th percentile), which together account for the majority of the composite score. Offsetting weakness in investment (21th percentile) and momentum (25th percentile) tempers our overall conviction. We assign a No Moat rating (38/100), Low uncertainty, and Standard capital allocation.
Key items to watch: momentum to confirm whether the current price trend has legs; sustainability of the current growth rate. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
KEWAUNEE SCIENTIFIC CORP /DE/ holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 47.7/100 places it at rank #2374 in our full 7,333-stock universe. At $120M in market capitalization, KEWAUNEE SCIENTIFIC CORP /DE/ is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue is growing at 45%, though momentum at the 25th percentile suggests the market has not yet fully recognized this trajectory. This potential disconnect between fundamental improvement and market recognition could represent an opportunity for patient investors if the growth trend persists.
The margin cascade tells an important story: gross margins of 29% (-14.0pp vs sector) narrow to operating margins of 6% (+5.0pp vs sector) and net margins of 4.1%, yielding a gross-to-net conversion rate of 14%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $43.14, KEWAUNEE SCIENTIFIC CORP /DE/ is trading near fair value based on current fundamentals. Our value factor score of 68/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. Valuation metrics are mixed, with no strong signal of mispricing in either direction.
The stock currently trades at a P/E of 12.1x (a 46% discount to the sector median of 22.3x), EV/EBITDA of 10.1x (near the sector median), P/B of 1.7x, P/S of 0.5x. The below-sector P/E suggests possible undervaluation or the market pricing in near-term headwinds.
Revenue growth of 45% confirms the business is expanding its addressable market — growth at this level typically supports multiple expansion and attracts institutional capital.
A value factor score of 68/100 suggests the market is underpricing these fundamentals, creating a potential margin of safety for new investors.
The Reduce rating (composite 47.7/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Weak momentum (25th percentile) suggests institutional selling pressure and unfavorable technical dynamics that may persist.
We assign a Low uncertainty rating to KEWAUNEE SCIENTIFIC CORP /DE/. The company exhibits strong financial stability with a beta of 1.07, conservative leverage (49% D/E), and a stability factor in the 58th percentile. The predictable nature of the business model and solid financial position reduce the range of potential outcomes, giving us confidence in our fair value estimate.
We identify no major risk factors at this time. The company's stability factor sits at the 58th percentile with quality at the 65th percentile, both of which support our low-risk assessment. The absence of material leverage, profitability, or volatility concerns reduces the likelihood of a permanent capital loss scenario.
We identify limited risk mitigants at this time, which contributes to our low uncertainty assessment. Investors should monitor for improvement in balance sheet metrics, margin stability, and business predictability that could warrant a downgrade in our risk assessment over time.
We rate KEWAUNEE SCIENTIFIC CORP /DE/'s capital allocation as Standard. Management has shown adequate — though not exceptional — stewardship of shareholder capital. Returns on equity stand at 14.1%, and the balance sheet is managed within acceptable parameters (D/E: 49%). Exemplary allocators typically sustain ROE above 20% and D/E below 50%; KEWAUNEE SCIENTIFIC CORP /DE/ falls short on at least one dimension.
There is room for improvement in optimizing the capital structure or enhancing shareholder returns. Absent a dividend, the overall capital allocation framework would benefit from either higher reinvestment returns, improved balance sheet efficiency, or increased shareholder distributions. We will monitor for signs of strategic improvement that could warrant an upgrade.
In summary, KEWAUNEE SCIENTIFIC CORP /DE/ receives a Reduce rating with a composite score of 47.7/100 (rank #2374 of 7,333). Our quantitative framework assigns a No Moat (38/100, trend: stable), Low uncertainty, and Standard capital allocation. The average factor score across quality, value, momentum, stability, and investment is 47/100.
Our analysis does not support a constructive view on KEWAUNEE SCIENTIFIC CORP /DE/ at this time. The combination of limited competitive advantages, low uncertainty, and standard capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign KEWAUNEE SCIENTIFIC CORP /DE/ a meaningful economic moat, scoring 38/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, growth durability, reached only 14/20.
The strongest moat sources are growth durability (14/20) and margin superiority (10.2/20). Rev growth 45%, 11yr history. GM 29% vs sector 43%, OM 6% vs sector 1%. These pillars form the core of KEWAUNEE SCIENTIFIC CORP /DE/'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (0/20) and economic value creation (6.5/20). Capital turnover N/A. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect KEWAUNEE SCIENTIFIC CORP /DE/'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include robust top-line growth of 45% expanding the revenue base. The margin cascade from 29% gross to 6% operating to 4.1% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that the profit engine is high-quality and likely sustainable, with the quality factor at the 65th percentile.
The margin profile shows gross margins of 29%, operating margins of 6%, net margins of 4.1%. Return metrics include ROE of 14.1% and ROA of 5.3%. Relative to the Manufacturing sector, gross margins are 14.0 percentage points below the sector median of 43%, and ROE of 14.1% compares to a sector median of -2.5%.
The balance sheet reflects moderate leverage with D/E of 49%, revenue growth of 45%. The sector median D/E is 0%, putting KEWAUNEE SCIENTIFIC CORP /DE/ at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Above 50MA
37.18%
Net New Highs
+51081
There are a few key trends to look for if we want to identify the next multi-bagger. Typically, we'll want to notice a...
Eli Lilly, Marriott and Fortinet lead Zacks' top analyst picks after earnings beats and strong outlooks across pharma, travel and cybersecurity.
When you buy a stock there is always a possibility that it could drop 100%. But on a lighter note, a good company can...
Analyst reports spotlight Agnico Eagle Mines as it executes growth projects, benefits from higher gold prices, and strengthens its position after major deals.
Shares of Methode Electronics, Inc (NYSE: MEI) fell sharply during Thursday’s session following weak quarterly earnings. Methode Electronics posted adjusted earnings of 6 cents per share, missing market estimates of 12 cents per share. The company’s quarterly sales came in at $288.00 million versus expectations of $292.82 million, according to Benzinga Pro. Methode Electronics shares fell 14.2% to $20.92 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Save Foods, Inc. (NASDAQ: SVFD) shares climbed 186.7% to $6.16 after the company highlighted targeting of US carbon credit market following acquisition of majority ownership in newly- formed Nitrousink Ltd. Cyngn Inc. (NASDAQ: CYN) gained 90.4% to $0.4643 after the company announced the issuance of a new patent, US-11,837,089-B2, for the autonomous vehicle (AV) and driving solutions. Barnes & Noble Education, Inc. (NYSE: BNED) shares climbed 31.9% to $1.3850 following upbeat quarterly earnings. Hempacco Co., Inc. (NASDAQ: HPCO) shares climbed 28.8% to $0.4331 after the company announced it entered into an exclusive Master Distribution Agreement with CBDAY Global. Under the agreement, CBDAY will exclusively sell Hempacco's line of hemp and CBD products in India and Thailand. MicroAlgo Inc. (NASDAQ: MLGO) shares gained 26% to $12.07. MicroAlgo shares jumped over 295% on Wednesday after the company announced it plans to establish a postgraduate training practice base. Kewaunee Scientific Corporation (NASDAQ: KEQU) climbed 25.5% to $22.53 following second-quarter earnings. Inogen, Inc. (NASDAQ: INGN) climbed 23.3% to $6.15. Satellogic Inc. (NASDAQ: SATL) rose 22% to $1.9584. Uzma and Satellogic signed a multi-million dollar +3-year agreement to advance geospatial capabilities in Southeast Asia. Fitell Corporation (NASDAQ: FTEL) gained 19.7% to $1.70. Altisource Asset Management Corporation(NYSE: AAMC) gained 19.3% to $4.0213. Altisource Asset Management reported key ruling in Blackrock and PIMCO litigation. Semtech Corporation (NASDAQ: SMTC) climbed 18.5% to $19.80 after the company reported third-quarter financial results and issued guidance. Altimmune, Inc. (NASDAQ: ALT) gained ...